Bladder cancer is a common and expensive malignancy in the UK, yet it is critically under-recognised, leading to late diagnosis and declining patient outcomes, with five-year survival rates worsening. Key issues include poor public and GP awareness, significant treatment delays, a lack of updated clinical guidelines and new treatment options for many years, and major variations in care due to the absence of a national audit. Read more about the bladder cancer landscape in this report.
